Related Experiment Videos
[Therapeutic choices in silent ischemia]
J P Bounhoure1, M Galinier, J P Albenque
1Service de cardiologie, CHU Toulouse Rangueil.
Insights
Silent myocardial ischemia, often painless, indicates coronary insufficiency and risks serious cardiac events. Treatment should prioritize addressing ischemia severity and coronary anatomy over functional impairment alone.
Area of Science:
- Cardiology
- Ischemic Heart Disease
- Coronary Artery Disease
Context:
- Silent myocardial ischemia is a frequent manifestation of coronary insufficiency.
- It is linked to significant risks including heart attack, arrhythmias, and sudden cardiac death.
- Pathophysiology involves complex, transient coronary flow changes due to vasomotricity abnormalities.
Purpose:
- To highlight the significance of silent myocardial ischemia.
- To emphasize the need for accurate evaluation and appropriate treatment.
- To advocate for a shift in therapeutic strategies.
Summary:
- Silent myocardial ischemia, even without pain, necessitates thorough coronary assessment and risk factor management.
- Treatment should focus on reducing ischemic episodes and addressing underlying coronary lesions.
- Evaluation includes risk factor analysis, therapeutic trials, and potentially coronary angiography.
Impact:
- This approach modifies traditional treatment paradigms for coronary insufficiency.
- Prioritizes intervention based on ischemic severity and anatomical findings.
- Aims to improve outcomes by directly targeting the disease process.
Abstract:
Silent or painless myocardial ischaemia is a common presentation of coronary insufficiency. Repeated episodes lead to anatomical and functional myocardial changes and are associated with the risk of ischemic cardiomyopathy, infarction, arrhythmias and sudden death. The physiopathology is complex and involves transient changes in coronary flow secondary to abnormalities of coronary vasomotricity. It is commonly observed in association with symptomatic angina, in unstable angina and after acute myocardial infarction. In all cases, appropriate treatment is required, the aim being to decrease and suppress not only pain but also ischaemia. Treatment is guided by the ischemic episodes. "Isolated" silent myocardial ischaemia as the only sign of coronary insufficiency justifies accurate evaluation of the coronary status, risk factors and a therapeutic trial, followed by systematic coronary angiography if the ischaemia persists. Silent myocardial ischaemia has modified classical therapeutic attitudes in which the choice of treatment is based on the severity of functional impairment. Priority should now be given to treating the severity of the ischaemia and of the anatomical lesions.